Evolus reports Q3 EPS (98c), consensus ($1.13)
Reports Q3 revenue $13.2M, consensus $4.05M. "This was an exceptional quarter for the company on many fronts, in the U.S. and internationally," said David Moatazedi, President and Chief Executive Officer. "In our first full quarter on the U.S. market, we reported $13.2 million in net revenue and Jeuveau captured the number three market position. We established a broad base of over 2,000 accounts ordering Jeuveau. During the third quarter, re-orders represented an increasing portion of our revenue with a steady increase of new accounts month-over-month. Internationally, we obtained approval for Nuceiva in the European Union giving us access to 31 countries across Europe and we look forward to commercial launch in 2020. Additionally, Nuceiva recently launched in Canada."